Cartalax

Cartalax (also known as AED, T-31, or Ala-Glu-Asp) is a synthetic tripeptide consisting of alanine, glutamic acid, and aspartic acid.

Developed within the framework of Russian peptide bioregulator research at the St. Petersburg Institute of Bioregulation and Gerontology, it is classified as a cytomedine designed to target cartilage and connective tissues.

The peptide functions by modulating gene expression in chondrocytes and thyroid C cells to support joint health.

Its primary mechanisms include:

• Promoting Collagen Synthesis: Upregulating genes involved in cartilage matrix production, specifically type II collagen and proteoglycans.
• Anti-Inflammatory Action: Inhibiting matrix metalloproteinases (MMPs) and suppressing pro-inflammatory cytokines to reduce cartilage degradation.
• Cell Protection: Reducing apoptosis (programmed cell death) in stressed cartilage cells and supporting cellular resilience under oxidative stress.

Research suggests Cartalax aids in cartilage repair, joint mobility, and slowing degenerative changes associated with osteoarthritis and aging.

It is distinct from broad tissue-repair peptides like BPC-157 due to its specific targeting of cartilage signaling pathways. While used in some regional medical contexts, global clinical trials are limited, and it is not FDA-approved for human use, often being sold internationally as a research peptide or dietary supplement.